Aditxt Acquires Ignite Proteomics for $36 Million

10x Genomics Acquires Proteintech Genomics to Expand Proteomics Capabilities

June 10, 2026

Biotechnology

10x Genomics announced it has acquired Proteintech Genomics, a division within Proteintech Group, to expand its proteomics capabilities for single-cell and spatial multiomics workflows on 10x platforms. The deal adds Proteintech Genomics’ Human Discovery Panel technology and supports 10x’s strategy of integrating transcriptomic and proteomic measurements, including capabilities planned for its Atera platform. Financial terms were not disclosed.

Copley Acquisition Corp and Aditxt Agree to Take Ignite Proteomics Public via Business Combination Valuing Company at ~$150 Million

June 9, 2026

Biotechnology

Copley Acquisition Corp and Ignite Proteomics (a wholly owned subsidiary of Aditxt) have entered into a definitive business combination agreement to take Ignite public. The transaction values Ignite at an implied equity value of approximately $150 million and is expected to create a newly formed holding company (Ignite Proteomics Holdings) with listings on the NYSE, with Ignite expected to become an independent public company following closing.

Illumina Acquires SomaLogic from Standard BioTools

January 30, 2026

Healthcare Services

Illumina, Inc. completed its acquisition of SomaLogic, adding data-driven proteomics technology to expand its multiomics portfolio. The deal was for $350 million in upfront cash at closing, plus up to $75 million in near-term performance-based milestones/royalties, with Illumina expecting to fund the transaction with cash on hand.

Aditxt Acquires Appili Therapeutics

October 10, 2024

Healthcare Services

Aditxt, Inc. announced that Appili Therapeutics shareholders will vote on a proposed acquisition of all issued and outstanding shares of Appili through a plan of arrangement. Appili’s board recommended shareholders vote in favor, and Aditxt intends to use Appili’s infectious disease pipeline (including the FDA-approved LIKMEZ) to expand its reach in combating life-threatening infections and biodefense threats.

Inotiv Acquires Protypia to Expand Protein/Peptide Bioanalytical Capabilities

July 7, 2022

Healthcare Services

Inotiv, Inc. completed the acquisition of Nashville-based Protypia, Inc., a protein/peptide bioanalytical company, for approximately $11.0 million in a combination of cash, Inotiv common shares and promissory notes. The deal adds quantitative tissue-based large-molecule mass spectrometry capabilities to Inotiv's bioanalytical offerings to support immuno-oncology, cell and gene therapy, and other drug development programs.

Insightful Science Acquires Protein Metrics

December 21, 2021

Software

Insightful Science, a portfolio company of Insight Partners, has acquired Protein Metrics, a provider of protein characterization and proteomics analysis software. The deal adds proteomics capabilities to Insightful Science's R&D software portfolio (including GraphPad Prism, SnapGene, Geneious Prime and Dotmatics) to help biopharma and research customers accelerate protein analysis across research and production.